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ABSTRACT

CmeABC, a multidrug efflux pump, contributes to Campylobacter resistance to a
broad spectrum of antimicrobial agents and is also essential for Campylobacter
colonization by mediation of bile resistance. We hypothesize that inhibition of CmeABC
will not only control antibiotic resistance but also increase the susceptibility of
Campylobacter to in vivo bile salts, consequently decreasing the colonization level of
Campylobacter. Using both in vitro and in vivo systems, we examined the effect of an
efflux pump inhibitor (EPI) MC-207,110 on the susceptibility of Campylobacter to
various antimicrobials. Presence of the EPI resulted in 2- to 2048-fold reduction in the
MICs of antimicrobials known to be substrates of CmeABC pump in all Campylobacter
strains. Particularly, the MICs of selected bile salts were dramatically decreased 64- to
512-fold when the EPI was used. The intrinsic and acquired resistance of C. jejuni to
macrolide was decreased significantly (32- to 64-fold reduction in the MIC of
erythromycin) in the presence of the EPI while the MICs of fluoroquinolones were only
slightly decreased (2-4 folds). Investigation of 57 clinical Campylobacter isolates of
various origins further showed that the EPI decreased the MICs of erythromycin (2- to
512-fold) in all isolates. Compared to wild-type strains, the isogenic CmeB mutants
displayed much lower magnitude of reduction in the MICs of antimicrobials in the
presence of the EPI. The inhibitory effect of the EPI was does-dependents and as low as
0.5 μg/ml of the EPI resulted in decreased MIC of antimicrobials in C. jejuni. Presence
of the EPI decreased the frequency of emergence of erythromycin-resistant mutants in C.
jejuni (<10-11), which is well below normal frequency of approximate 10-8. Notably, MIC
iv

of erythromycin was also greatly decreased (> 4-fold) in CmeB mutants in the presence
of EPI, suggesting the existence of other pump(s) involved in macrolide resistance in C.
jejuni. Chicken colonization study demonstrated that oral administration of EPI
dramatically reduced the colonization of Campylobacter in the intestine. In addition,
anti-CmeC antibodies also enhanced the susceptibility of C. jejuni to bile salt, suggesting
immune intervention by targeting CmeC may be another effective strategy to inhibit
CmeABC efflux pump. Together, these findings indicate that inhibition of CmeABC by
specific EPI or antibodies is a promising approach to control antibiotic resistance and
colonization of Campylobacter in human and animals.

Key Words: Campylobacter, efflux pumps, efflux pump inhibitors
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1. REVIEW OF LITERATURE

Campylobacter and the Poultry Reservoir

Campylobacter, a microaerophilic Gram-negative bacterium, is the leading
foodborne human pathogen in the United States and many other industrialized countries
(Altekruse et al., 1999; Friedman et al., 2000). There are an estimated 2.1 to 2.4 million
reported cases in the United States each year, with even more cases going unreported
(Mead et al., 1999). Medical and production costs associated with Campylobacter
average 1.5 to 8.0 billion dollars each year in the United States (Buzby et al., 1997). This
pathogenic organism causes watery diarrhea, hemorrhagic colitis, and even severe
abdominal pain (Skirrow and Blaser, 2000). In rare cases Campylobacter can also be
associated with Guillian-Barre syndrome, which is an autoimmune disease that may lead
to respiratory muscle compromise and death (Nachamkin et al., 1998). The infective
dose can be as low as 5-800 organisms (Black et al., 1988). Through oral ingestion, C.
jejuni enters the host intestine via stomach acid barrier and colonizes the distal ileum and
cecum. There are more than 14 different species of Campylobacter. However, human
Campylobacter illness are primarily caused by C. jejuni (>99%) and secondarily by C.
coli (Allos et al., 2001). Growth conditions for C. jejuni are very specific. C. jejuni
survive poorly outside of intestine and replication does not occur readily in the
environment. C. jejuni requires optimal growth temperatures between 37 oC and 42 oC.
In addition, C.jejuni grows best in a microaerophilic environment, such as an atmosphere
of 5% O2, 10% CO2, and 85% N2. Although these growth conditions are stringent,
1

Campylobacter is still able to cause more infections than Salmonella, Shigella and E. coli
O157 (Altekruse et al., 1999).

Although Campylobacter is widely present in wild and domestic animals (JacobsReitsma et al., 1997, 2000), poultry are considered the major reservoir of Campylobacter,
because this organism is highly prevalent in poultry and the majority of human
campylobacteriosis are epidemiologically linked to consumption of contaminated poultry
products (Allos et al., 2001). Campylobacter is also highly prevalent in market-age
broiler chickens and turkeys raised on organic or free-range farms (Avrain et al., 2003;
Heuer et al., 2001; Rivoal et al., 1999), indicating that different production systems are
equally vulnerable to invasion by this organism. Besides chickens and turkeys,
Campylobacter species also infect ducks, ostriches, and geese (Aydin et al., 2001;
Wallace et al., 1998; Yogasundram et al., 1989). Campylobacter is carried in the
intestinal tract of birds and excreted in feces. The number of Campylobacter in intestinal
contents of broiler chickens can be as high as 108 CFU g-1 feces (Stern et al., 1995;
Wempe et al., 1983). Although market-age broilers and turkeys are highly contaminated
by Campylobacter, the prevalence in individual flocks varies greatly depending on the
age of birds (Berndtson et al., 1996; Evans and Sayers, 2000; Kazwala et al., 1990;
Shanker et al., 1988). Campylobacter is rarely detected in broiler chickens less than 2-3
weeks old under commercial production conditions, although newly hatched chickens can
be experimentally infected with this pathogen (Sahin et al., 2002; Stern et al., 1988;
Young et al., 1999). For the majority of commercial flocks, Campylobacter infection is
usually detected after the third week of age (Newell and Fearnley, 2003; Sahin et al.,
2

2002). Once a flock is infected by Campylobacter, most birds soon become colonized
and shed large numbers of the organism. Despite persistent and extensive colonization in
chickens, this organism does not cause clinical disease in the poultry host under natural
conditions (Beery et al., 1988; Meinersmann et al., 1991). In poultry processing plants,
carcasses and edible parts are often contaminated with C. jejuni, largely through contact
with fecal materials. Hence, a large number (up to 100% in summer months) of retail
broilers is contaminated with C. jejuni (Ge et al., 2003; Willis and Murray, 1997), posing
a major threat to public health.

Horizontal transmission, or transmission within a population, is a major
mechanism of infection of Campylobacter among chicken flocks. Possible sources
include feces, untreated drinking water, other farm animals, domestic pets, wildlife
species, house flies, insects, equipment, transport vehicles and farm workers (Sahin et al.,
2002). However, the most likely source of infection comes from one infected chicken
passing it to another in a rapid fire succession. While most evidence supports the theory
of horizontal transmission, it is likely that Campylobacter infection is also mediated by
vertical transmission, which is the transmission from hen to chick at the time of laying
and/or hatching. Reasoning behind this theory is that Campylobacter can be isolated
from chicken eggs and in some cases from newly hatched chicks (Sahin et al., 2002).

3

Antibiotic Resistance in Campylobacter

Development of antibiotic resistance is inevitable in bacteria, including
Campylobacter, and every antibiotic that is introduced into market to date has limited
time before it is no longer effective (Walsh et al., 2003). In general, Campylobacter
resistance to antibiotics is mediated by three mechanisms, including 1) synthesis of
enzymes (e.g. β-lactamase) that modify or inactivate antibiotics, 2) alteration or
protection of targets that results in reduced affinity to antibiotics (e.g. mutations in gyrA),
and 3) active extrusion of drugs from Campylobacter cells through efflux transporters
(e.g. CmeABC). Detailed information on resistance mechanisms to different classes of
antibiotics has been provided in recent reviews (Taylor and Tracz, 2005; Snelling et al.,
2005; Trieber and Taylor, 2000). Antibiotic-resistant Campylobacter strains have rapidly
increased throughout the world in the past decade, compromising the clinical
effectiveness of antimicrobial treatments (Engberg et al., 2001; Taylor and Tracz, 2005).
The factors contributing to the rising resistance are complex, and the extensive use of
antimicrobial agents in human medicine and agriculture is considered the main driving
force for the worldwide progression of antibiotic resistance in Campylobacter (Smith et
al., 2000).

The increasing resistance of C. jejuni to fluoroquinolones (FQs) and macrolides,
the two drugs of choice for treating human campylobacteriosis, has become a major
concern for public health. FQs target bacterial DNA gyrase and topoisomerase IV, which
catalyze the ATP-dependent negative supercoiling of DNA and are involved in DNA
4

replication, recombination, and transcription (Trieber and Taylor, 2000; Taylor and
Tracz, 2005; Zhang et al., 2003). Recent studies indicate that Campylobacter displays a
hypermutable phenotype in response to in vivo treatment of poultry with FQ antibiotics,
resulting in rapid emergence of FQ-resistant mutants in poultry (Luo et al., 2003;
McDermott et al., 2002). Therefore, on July 28, 2005, the FDA issued a ban on the use of
Baytril in poultry (an antibiotic nearly identical to FQ ciprofloxacin) to protect public
health (see www.fda.gov/bbs/topics/news/2005/new01212.html). Distinct from other
Gram-negative bacteria, acquisition of FQ resistance in Campylobacter does not require
stepwise accumulation of gyrA mutations and overexpression of efflux pumps, and is
mainly mediated by single-step point mutations in gyrA in the presence of a constitutively
expressed multidrug efflux pump (Zhang et al., 2003).

FQs are losing effectiveness in clinical treatments due to the widespread
resistance of Campylobacter to this class of antimicrobials (Engberg et al., 2001; Smith
et al., 1999). Consequently, erythromycin (a macrolide) is considered a best option for
treating Campylobacter infections. Unfortunately, Campylobacter resistance to
macrolides is also on the rise (Engberg et al., 2001). Macrolide antibiotics inhibit
bacterial protein synthesis by binding to the 50S subunits of ribsome (Engberg et al.,
2001; Taylor and Tracz, 2005; Trieber and Taylor, 2000). Campylobacter resistance to
macrolides results from chromosomal mutations in the 23S RNA gene, which lead to
reduced binding of macrolide antibiotics to the 50S subunit of ribosome (Engberg et al.,
2001; Taylor and Tracz, 2005). Specifically, the A-2230-G mutation is associated with
the majority of erythromycin-resistant Campylobacter (Ge et al., 2003; Jensen and
5

Aarestrup, 2001; Gibreel et al., 2005). Multidrug efflux pump CmeABC also plays an
important role in the intrinsic and acquired resistance to macrolides (Mamelli et al., 2005;
Lin et al., 2002). Other mechanisms such as methylation, which is involved in macrolide
resistance in other bacteria, have not been associated with macrolide resistance in
Campylobacter (Trieber and Taylor, 2000).

The reported macrolide resistance rates vary with Campylobacter species and the
animal hosts. In general, C. coli has higher erythromycin resistance rates than C. jeuni,
regardless of the source of isolation (Engberg et al., 2001; Saenz et al., 2000; Van
Looveren et al., 2001). Likewise, pigs and turkeys tend to harbor higher numbers of
erythromycin-resistant Campylobacter than other animal species. For example, a recent
study in Italy reported that 3.1% C. jejuni and 45% C. coli from broilers are resistant to
erythromycin, while 42.6% C. coli from pigs and 24.1% C. coli from humans are
resistant to the same antibiotics (Pezzotti et al., 2003). Another study conducted in France
showed erythromycin resistance in 0.3% Campylobacter from broiler chicken and 31%
from turkey (Avrain et al., 2003). A recent survey of retail meats conducted in the U.S.
showed that 40-50% Campylobacter isolates from chicken and 90-100% Campylobacter
isolates from turkey were resistant to erythromycin (Ge et al., 2003).

General Features of MDR Efflux Pumps in Gram-Negative Bacteria

As a general and important mechanism for antimicrobial resistance, multidrug
efflux systems (often named MDR pumps) contribute significantly to antimicrobial
6

resistance by extruding structurally diverse antimicrobial agents out of bacterial cells
(Poole, 2001a; Putman et al., 2000). In pathogenic bacteria, there are many different
types of multidrug efflux systems which vary in size, structure, and energy source (proton
gradient or ATP hydrolysis (Putman et al., 2000). In general, MDR efflux pumps can be
categorized into five different superfamilies, including MFS (major facilitator
superfamily), SMR (small multidrug resistance), RND (Resistance-Nodulation-cell
Division), MATE (multidrug and toxic compound extrusion), and ABC (ATP-binding
cassette) (Putman, 2000). These efflux systems are broadly distributed and a single
microorganism can have multiple efflux transporters of different families with
overlapping substrate spectra (Poole, 2001a; Putman et al., 2000).

One major and important family of MDR pumps in Gram-negative bacteria is
RND efflux system, which consists of an inner membrane transporter, a periplasmic
fusion protein, and an outer membrane protein (Zgurskaya and Nikaido, 2000). These
three components function together and form a membrane pump to extrude
antimicrobials out of cells. Genetically, many of the RND-type MDR efflux systems are
encoded by three-gene operons located on bacterial chromosomes (Zgurskaya and
Nikaido, 2000; Paulsen et al., 2001). However, some RND-type efflux pumps, such as
AcrAB from Escherichia coli (Ma et al., 1993), have an outer membrane component that
is encoded by a separate gene physically unlinked with the other two members on the
bacterial chromosome. More detailed information about molecular properties of various
types of bacterial MDR transporters is discussed in an excellent review by Putman et al.
(2000).
7

A key feature of these MDR efflux systems, particularly RND type pump, is their
ability to extrude a broad spectrum of substrates including various clinically relevant
antibiotics (Poole, 2001a; Putman et al., 2000). Overexpression of RND-type efflux
pumps results in a MDR phenotype in bacterial pathogens and is considered a major
mechanism of antibiotic resistance in a growing number of pathogenic bacteria (Poole,
2001a; Putman et al., 2000; Van Bambeke et al., 2000). Even without overexpression,
constitutively expressed MDR pumps function synergistically with other non-efflux
resistance mechanisms (such as target mutations) to confer high levels of antimicrobial
resistance in bacteria (Lomovskaya et al., 1999; Oethinger et al., 2000; Wang et al., 2001;
Luo et al., 2003). The RND-type efflux systems also play an important role in bacterial
resistance to a variety of antimicrobial compounds that are naturally present in animal
hosts (e.g. bile salts) (Poole, 2001a; Putman et al., 2000; Gunn, 2000; Lin et al., 2003b;
Thanassi et al., 1997; Rosenberg et al., 2003). Major natural function of RND efflux
system is proposed to be involved in the in vivo adaptation in various host niches (e.g.
bile resistance in intestine) during infections (Poole, 2001a; Lin et al., 2003b; Lin et al.,
2005b; Webber and Piddock, 2003).

The expression of bacterial MDR efflux pumps is usually controlled by
transcriptional regulators that either repress or activate the transcription of the MDR
efflux genes (Grkovic et al., 2002; Poole, 2001a). Many of these regulators are local
repressors that directly interact with the promoter regions of MDR efflux genes or
operons. The operator sequences that interact with the repressor molecules usually
consist of inverted repeats (Grkovic et al., 2002). Mutations in the repressors or
8

repressor-binding regions impede the repression and result in overexpression of efflux
pumps, which consequently increases bacterial resistance to structurally unrelated
antimicrobial agents (Grkovic et al., 2002; Poole, 2001a; Putman et al., 2000). Some
MDR efflux systems are also controlled by global regulators, such as the marRAB
regulon in E. coli (Alekshun and Levy, 1999b). MarR is a repressor of marRAB, while
marA encodes an activator that not only positively regulates marRAB but also activates a
variety of genes (including acrAB) associated with resistance to antibiotics and oxygen
stress (Alekshun et al., 2000; Alekshun and Levy, 1999b). Mutations in marR
substantially increase the expression of acrAB and confer E. coli resistance to a variety of
antimicrobial agents (Alekshun and Levy, 1999a; Kern et al., 2000; Okusu et al., 1996).

In addition to the mutation-based mechanisms that result in sustained
overexpression of MDR efflux pumps in bacteria, the production of some MDR efflux
pumps can be conditionally induced by structurally diverse substrates or by stress signals
(Ahmed et al., 1994; Brooun et al., 1999; Grkovic et al., 1998; Kaatz and Seo, 1995; Kato
et al., 1992; Ma et al., 1995; Masuda et al., 2000). This induction is usually due to the
direct interaction of the substrates with repressor molecules, which interferes with the
binding of repressors to operator DNA and results in increased expression of MDR genes.
Two repressors (QacR and AcrR) of such inducible MDR efflux pumps belong to the
TetR family of transcriptional regulators, which share a conserved helix-turn-helix DNAbinding motif at their N-terminal regions and have divergent C-terminal sequences that
are involved in the binding to inducing compounds (Grkovic et al., 1998; Hillen and
Berens, 1994).
9

Multidrug Efflux Systems in Campylobacter

In contrast to the situation with specific resistance mechanisms, such as target
mutations and enzyme modifications, little is known about the general antibiotic efflux
mechanisms in Campylobacter. In an early study (Charvalos et al. 1995), MDR C. jejuni
isolates were selected by in vitro passage of the organism on pefloxacin-containing
plates. These isolates were not only resistant to FQs, but also resistant to other
structurally unrelated antibiotics. The results showed that resistant strains had less
accumulation of antimicrobial substances than did wild-type strains, indicating the
presence of MDR efflux pump systems (Charvalos et al., 1995). However, the identities
of putative MDR pumps and their role in efflux of antibiotics were not determined
(Charvalos et al., 1995). The genomic sequence of C. jejuni NCTC 11168 revealed
several genes that share sequence homology with known MDR efflux pumps in bacterial
pathogens (Parkhill et al., 2000). Recently, two RND type multi-drug efflux pumps
CmeABC and CmeDEF have been identified and functionally characterized (Akiba et al.,
2006; Lin et al., 2002, 2003, 2005a, b; Luo et al., 2003; Guo et al., 2005).

MDR efflux pump CmeABC is encoded by a three-gene operon which encodes
for CmeA (periplasmic linker protein), CmeB (inner membrane protein) and CmeC (outer
membrane protein) (Lin et al., 2002). Inactivation of the CmeABC pump by insertional
mutagenesis substantially increased the susceptibility of C. jejuni to structurally diverse
antimicrobial agents, including FQs, β-lactams, erythromycin, rifampin, ethidium
bromide, heavy metals, detergents and various bile salts (Lin et al., 2002, 2003; Pumbwe
10

and Piddock, 2002). This phenotypic change can be observed in different strain
backgrounds. Insertional mutation in cmeC resulted in the same changes in antibiotic
susceptibility as those caused by cmeB mutation (Lin et al., 2003), indicating that
inactivation of a single component in the system would cause malfunction of the
CmeABC pump and further supporting the notion that the three members of CmeABC
function together in the efflux of substrates (Lin et al., 2002). The dramatic change in
antibiotic susceptibility caused by inactivation of CmeABC in different Campylobacter
strains suggests that this pump is a main player in mediating intrinsic resistance to
antibiotics. Although the role of CmeABC in the acquired antibiotic resistance in
Campylobacter has not been well understood, partly because overproduction of CmeABC
has not been linked to antibiotic resistance in clinical isolates, several studies (Lin et al.,
2002; Luo et al., 2003; Mamelli et al., 2005) provide compelling evidence that CmeABC
can work synergistically together with other nonefflux mechanisms to confer high level
of resistance to clinically important antibiotics, such as FQs and macrolides. PCR and
immunoblotting analysis showed that cmeABC was broadly distributed in various C.
jejuni isolates and constitutively expressed in wild-type strains.

One striking feature of CmeABC is its essential role in C. jejuni resistance to bile,
a group of bactericidal detergents present in the intestinal tracts of animals (Lin et al.,
2003, 2005b). This is a very important aspect because the efflux of these bile salts can
allow Campylobacter to establish colonization without hindrance from the body’s natural
defense mechanisms. Inactivation of CmeB or CmeC resulted in malfunction of the
CmeABC pump and drastically increased susceptibilities of C. jejuni to various bile salts.
11

Addition of choleate (2 mM) in culture media impaired the in vitro growth of the cmeC
mutant, but had no effect on the growth of the wild-type strain. Bile concentration varied
in duodenum, jejunum, and cecum of chicken intestine and the inhibitory effect of the
intestinal extracts on the in vitro growth of Campylobacter was well correlated with the
total bile concentration in the individual sections of chicken intestine. When inoculated
into chickens, the wild-type strain colonized the birds as early as day 2 post-inoculation
with a density as high as 107 CFU/g feces. In contrast, both cmeB and cmeC mutants
failed to colonize any of the inoculated chickens throughout the study. The minimum
infective dose for CmeABC mutant is at least 2.6 × 104 fold higher than that of the wildtype strain. Complementation of the cmeABC mutants with a wild-type cmeABC allele in
trans fully restored the in vitro growth in bile-containing media and the in vivo
colonization to the levels of the wild-type strain. These results provide compelling
evidence that CmeABC, by mediating resistance to bile salts in the intestinal tract, is
required for successful colonization of C. jejuni in host.

A recent study demonstrated that CmeABC efflux system is subject to regulation
by CmeR, a transcriptional repressor encoded by a gene immediately upstream of
cmeABC operon (Lin et al., 2005a). CmeR represses the transcription of CmeABC by
directly binding to the promoter region of the CmeABC operon. Mutations either in
CmeR or in the inverted repeat impedes the repression and leads to overexpression of
CmeABC in Campylobacter (Lin et al., 2005a). In addition to mutation-based
mechanisms that resulted in sustained overexpression of CmeABC efflux pump as
described above, CmeABC efflux pump can be conditionally induced by bile salts, a
12

group antimicrobial agents naturally present in intestine (Lin et al., 2005b). The
induction is in a dose- and time-dependent manner and is mediated by the direct
interaction of bile salts with repressor CmeR. Since CmeABC is essential for bile
resistance, the inducible expression of cmeABC by bile salts provides a flexible
mechanism for Campylobacter to adapt in the intestinal environments. This notion is
further supported by a recent study (Stintzi et al., 2005) in which the expression of
cmeABC was found to be highly up-regulated in rabbit ileal loops as determined by whole
genome microarray and real-time RT-PCR. The elevated transcription of cmeABC in the
rabbit ileal loops was likely the direct result of bile induction, although non-bile inducers
for cmeABC may also exist in the gut. Together, these findings highlight the significance
of CmeABC in Campylobacter adaptation to the intestinal environment in hosts and
CmeABC efflux system is an attractive therapeutic and vaccine target to prevent and
control Campylobacter infections.

Another RND type efflux system, CmeDEF, has also been identified recently in
C. jejuni (Pumbwe et al., 2005; Akiba et al., 2006). Mutation in CmeDEF only resulted
in moderate decrease in the resistance to antibiotics (Pumbwe et al., 2005; Akiba et al.,
2006). The cmeB/cmeF double mutation, not the single mutations, impaired cell viability
in Campylobacter (Akiba et al., 2006). These findings indicate that CmeABC is the
predominant efflux pump in C. jejuni and CmeDEF interacts with CmeABC in conferring
antimicrobial resistance and maintaining cell viability in C. jejuni.

13

Based on the complete genome sequence of C. jejuni NCTC 11168 (Parkhill et
al., 2000) and comparative genomic analysis of MDR transporters (Paulsen et al., 2001),
bioinformatics analysis revealed 11 additional putative drug efflux proteins in C. jejuni,
including four putative MFS efflux pumps, four putative SMR type efflux pumps, one
putative ABC type efflux pump, and two putative MATE (Lin et al., 2005c). These
eleven putative efflux systems have not been characterized in detail. Recent study by Ge
et al. (2005) showed that mutations in most of these efflux pumps did not affect
susceptibility of C. jejuni to major antibiotics, suggesting that these putative efflux pumps
are of minimal importance in mediating antibiotic resistance and that CmeABC is the
main efflux system in Campylobacter species.

Efflux Pump Inhibitor

Efflux pump systems are increasingly recognized as a major and important
mechanism contributing to antibiotic resistance, particularly multi-drug resistance (MDR)
(Poole, 2005), which provide a strong rationale for industries to preserve and
significantly potentiate the efficacy of antimicrobial agents by interefering with efflux
pumps through small molecular inhibitors, also called efflux pump inhibitors (EPIs)
(reviewed in (Lomovskaya and Watkins, 2001b; Lomovskaya and Bostian, 2006; Kaatz,
2005)). It has been proposed that inhibiting MDR efflux systems by application of EPIs
is one approach to enhance drug accumulation inside the bacterial cell, thereby increasing
bacterial susceptibility to antimicrobials (Poole, 2001b; Lomovskaya and Watkins,
2001b). Since RND-type efflux pump is the most common and important MDR pump
14

implicated in clinically relevant resistance in gram-negative bacteria, the EPIs discussed
in this session are focused on those targeting RND-type efflux pumps. The information
regarding the EPIs inhibiting other types of efflux pumps can be found in recent reviews
(Lomovskaya and Watkins, 2001; Kaatz, 2005).

With the development of high-throughput screening system in the late 1990s,
Microcide and Daiichi Pharmaceuticals Co. identified the first EPI, MC-207,110 (PheArg β-naphthyl-amide dihydrochloride), that could effectively inhibit RND type efflux
pumps in P. aeruginosa (Lomovskaya et al., 2001a). This compound was subjected to
several growth assays, using Pseudomonas species, and was determined to be effective at
inhibiting the function of four clinically relevant RND type efflux pumps within those
species. Interestingly, there was a difference in the strength of the inhibitory effect of
EPI, had depending on the substrate. This information supports the idea that different
antimicrobials have different binding sites on the efflux pump (Lomovskaya et al.,
2001a). Further testing found that MC-207,110 was itself effluxed out of cells, indicating
that there is definitely an interaction between the efflux pump and MC-207,110
(Lomovskaya et al., 2001a). MC-207,110 appears to be a much better substrate of efflux
pumps than other antimicrobials and in a given instance, MC-207,110 would be
preferentially effluxed before other substrates, thus allowing antimicrobials more time to
exert their bactericidal effect (Lomovskaya et al., 2001a). In addition to the effect of
increasing the susceptibility to clinical antibiotics in wild-type strains of P. aeruginosa,
EPI MC-207,110 was also shown to reverse acquired resistance back to susceptible
phenotypes and decrease the frequency of emergence of antibiotic resistant strains
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(Lomovskaya et al., 2001a). Other studies showed that MC-207,110 is also effective
against a variety of Gram-negative bacteria, including E. coli (Saenz et al., 2004),
Enterobacter aerogenes (Chollet et al., 2004), Klebsiella pneumoniae (Hasdemir et al.,
2004), and Campylobacter (Mamelli et al., 2003). Together, these findings indicate that
MC-207,110 is very effective against RND-type efflux pumps, and is a promising agent
in combating MDR in Gram-negative bacteria.

Although there are a number of beneficial consequences of inhibition of efflux
pumps against MDR resistance, development of clinically useful EPIs is still in the early
stage (Lomovskaya and Bostian, 2006; Kaatz, 2005). Similar to all infectious disease
drug development, development of a promising EPI, such as MC-207,110, into a
clinically useful therapeutic agent must address key issues, such as stability,
bioavailability, production cost, etc. (Lomovskaya and Watkins, 2001; Lomovskaya and
Bostian, 2006; Kaatz, 2005). Mpex Pharmaceuticals, Inc. recently announced a Phase Ib
clinical trial to study an aerosol EPI candidate in Cystic Fibrosis patients, which is the
first time that a bacterial efflux pump inhibitor has been evaluated in humans for
controlling drug resistance (http://www.mpexbio.com/).

Campylobacter jejuni Vaccine Development

Despite growing need for new antibiotics owing to the inevitable development of
drug resistance in bacteria, pharmaceutical companies have been phasing out of the
antibiotic discovery field recently (Projan, 2003; Walsh, 2003). Therefore, in addition to
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searching potent EPIs for combination therapy as discussed above, development of other
intervention strategies, such as vaccination, to prevent and control Campylobacter
infections is also urgently needed. Host immunity plays an important role in antiCampylobacter infection in humans and animals. C. jejuni specific serum IgG, IgA, and
IgM, and mucosal IgG, IgA were rapidly increased after oral infection with C. jejuni
(Baqar et al., 2001; Wallis, 1994; Cawthraw et al., 1994). Among the different classes of
immunoglobulins, anti-Campylobacter intestinal or serum IgA is a major factor
contributing to the intestinal mucosal resistance to Campylobacter colonization (Wallis,
1994; Burr et al., 1988). Maternal IgA from human breast milk showed protective
immunity against enteric Campylobacter spp. (Renom et al., 1992). In a volunteer study,
re-challenge of previously infected volunteers could not reproduce the disease via
ingestion of C. jejuni 81-176, suggesting that immunity can be induced to protect
Campylobacter infections in humans (Black et al., 1988). Laboratory challenge
experiments indicated that anti-Campylobacter maternal antibodies partly contribute to
the lack of Campylobacter infection in young broiler chickens in natural environments in
the first two weeks (Sahin et al., 2001; Sahin et al., 2003). These findings strongly
support the feasibility of development of immunization-based approaches to control
Campylobacter infections.

There is no vaccine available to date to control Campylobacter infections. The
following three approaches have been explored for developing effective and safe C.
jejuni vaccine: 1) Live attenuated vaccines. Since challenge with wild-type C. jejuni
strain produced solid protective immunity in volunteers (Wallis, 1994), it is likely that
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live attenuated vaccine can confer protective effect. However, the paucity of information
on the pathogenesis of the organism complicates this strategy. On the other hand, some
C. jejuni strains that exhibit mimicry of gangliosides in their lipooligosaccharides are
associated with development of Guillain-Barre Syndrome, which makes live vaccine
potentially unsafe. C. jejuni strain 81-176 was proposed as a safe candidate for vaccine
design because of absence of persistent antiganglioside antibodies after experimental
infection with the strain (Prendergast et al., 2004; Scott and Tribble, 2000). 2) Killed
whole-cell vaccines. This type of vaccines could induce high protective immunity
without serious toxicity to the hosts. Vaccination of killed C. jejuni whole cell enhanced
the mucosal immune responses in human and chickens (Baqar et al., 1995; Baqar et al.,
1995; Rice et al., 1997; Widders et al., 1996; Prendergast et al., 2004) and partly reduced
colonization of C. jejuni (Widders et al., 1996; Baqar et al., 1995). 3) Subunit vaccine.
Subunit vaccine would have significantly less risk of post-vaccination sequelae than a
live attenuated or killed vaccine. However, few studies have been conducted to
characterize the immunological properties of protective antigens in C. jejuni, primarily
due to a lack of understanding of pathogenesis mechanisms and the antigenic complexity
of Campylobacter. Motility-mediating flagellum (Fla) is an immunodominant antigen
and is protective against C. jejuni infection in animal models (Guerry, 1997; Morooka et
al., 1985; Nachamkin et al., 1993; Pavlovskis et al., 1991; Wassenaar et al., 1993). Fla is
modified by glycosylation and undergoes both phase and antigenic variation, which
complicates the use of Fla for vaccination (Caldwell et al., 1985; Logan et al., 1989;
Szymanski et al., 1999; Doig et al., 1996). However, a truncated recombinant FlaA
subunit vaccine showed protection in an animal model (Lee et al., 1999). Oral
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immunization of chickens with CjaA that was expressed in a carrier strain elicited
specific immune response associated with protection against challenge with wild-type C.
jejuni (Wyszynska et al., 2004). However, the function of CjaA is still not clear. These
findings suggest that subunit vaccine may be a safe and feasible approach for
immunization against Campylobacter infections.
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2. INTRODUCTION

Campylobacter jejuni is the leading bacterial cause of human enteritis in many
industrialized countries (Slutsker et al., 1998; Friedman et al., 2000). The estimated
cases of campylobacteriosis in the United States are more than 2 million per year (Mead
et al., 1999). The medical costs and productivity losses resulting from C. jejuni infection
are estimated at 1.5 to 8.0 billion dollars each year in the United States (Buzby et al.,
1997; Buzby and Roberts, 1997). Campylobacter infections in humans vary from mild
diarrhea to severe cramping and abdominal pain (Skirrow and Blaser, 2000). This
pathogenic organism is also associated with Guillain-Bare syndrome, an auto immune
disease that may lead to respiratory muscle compromise and death (Nachamkin et al.,
1998). The majority of human C. jejuni infections are epidemiologically linked to
ingestion of contaminated poultry meat (Friedman et al., 2000; Tauxe, 2002), and the
infective dose can be as low as 5-800 organisms (Black et al., 1988; Mentzing, 1981). In
parallel to its increased prevalence, C. jejuni has become increasingly resistant to
antibiotics including macrolides and fluoroquinolones, the drugs of choice for treating
human campylobacteriosis, thus greatly compromising the effectiveness of antibiotic
treatments and posing a serious threat to public health (Engberg et al., 2001; Taylor and
Tracz, 2005). Therefore, development of effective strategies to prevent or eliminate
Campylobacter infections is urgently needed. To achieve this goal, it is essential to study
the mechanisms contributing to antibiotic resistance in Campylobacter and, on the other
hand, to develop an understanding of host-pathogen interaction, such as the mechanisms
utilized by Campylobacter to adapt in the intestinal environment in the presence of
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various antimicrobial agents (e.g. bile salts). Understanding the antibiotic resistance
mechanisms and the in vivo adaptation mechanisms may facilitate the development of
effective means to prevent and control Campylobacter infections in humans and animal
reservoirs.

As general and important mechanisms for antimicrobial resistance, multidrug
efflux systems (often named MDR pumps) contribute significantly to the intrinsic and
acquired resistance to antibiotics in bacterial organisms (Poole, 2001a; Putman et al.,
2000). In addition to being key players in antibiotic resistance, MDR pumps also
facilitate bacterial adaptation to deleterious environments where toxic compounds or
metabolites are present. Recently, a Campylobacter multidrug efflux pump (CmeABC)
contributing to antimicrobial resistance was characterized (Lin et al., 2002, 2003,
2005a,b; Luo et al., 2003; Pumbwe and Piddock, 2002). The CmeABC efflux system is
composed of three essential units, including an outer membrane protein (CmeC), an inner
membrane drug transporter (CmeB) and a periplasmic fusion protein (CmeA). These
three proteins are encoded by a three-gene operon (cmeABC) and function together to
form a membrane channel that extrudes toxic substrates directly out of Campylobacter
cells (Lin et al., 2002). CmeABC contributes significantly to the intrinsic and acquired
resistance of Campylobacter to structurally diverse antimicrobials (Lin et al., 2002; Luo
et al., 2003; Pumbwe and Piddock, 2002). In addition, CmeABC plays a key role in bile
resistance and is essential for Campylobacter growth in bile-containing media and
colonization in animal intestinal tract (Lin et al., 2003). These findings have defined the
importance of CmeABC in antimicrobial resistance and pathophysiology of
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Campylobacter. Notably, the CmeABC efflux pump can be dramatically induced by bile
salts, a group of antimicrobial agents naturally present in intestine (Lin et al., 2005b).
This notion is further supported by a recent study by Stintzi et al (2005), in which the
expression of cmeABC was found to be highly up-regulated in rabbit ileal loops as
determined by whole genome microarray and real-time RT-PCR. Together, these findings
highlight the significance of CmeABC in antibiotic resistance and in Campylobacter
adaptation to the intestinal environment in hosts. Thus, CmeABC efflux system is an
attractive target for the development of intervention strategies against Campylobacter
infections in humans and animal reservoirs.

It has been proposed that inhibition of MDR efflux systems by efflux pump
inhibitor (EPI) is a novel approach to enhance drug accumulation inside the bacterial cell,
thereby increasing bacterial susceptibility to antimicrobials (Ryan et al., 2001;
Lomovskaya and Watkins, 2001b). Recently, promising EPIs targeting the inner
membrane drug transporter of MDR efflux pumps have been discovered and
demonstrated to potentiate the activity of antimicrobial agents against a range of Gramnegative bacteria (Lomovskaya et al., 2001a). The presence of such inhibitors also
resulted in a decreased frequency of emergence of fluoroquinolone resistant mutants
(Lomovskaya et al., 2001a). Based on the unique features of CmeABC efflux pump as
described above, we speculate that inhibitors targeting the CmeABC efflux pump may
not only control antibiotic resistance but also increase the susceptibility of C. jejuni to in
vivo bile salts, consequently decreasing the colonization level of Campylobacter the in
host. Such pump inhibitors could be directly used as novel antimicrobials for therapeutic
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intervention of Campylobacter infection. The outer membrane component ,CmeC, is
essential for the function of CmeABC, immunogenic and inducible in vivo (Lin et al.,
2003; Lin et al., 2005b), it is likely CmeC antibodies will work similarly to EPI to inhibit
the functions of CmeABC pump in C. jejuni and provide immunity by targeting CmeC,
which may provide an alternative way to fight Campylobacter infections. To test our
hypothesis and achieve the goal of developing CmeABC-based intervention strategies
against Campylobacter, the following objectives were pursued in this study:
1) Determine the inhibitory effect of an EPI on the function of CmeABC efflux
pump and antibiotic resistance in Campylobacter.
2) Examine the effect of inhibition of CmeABC pump by an EPI on the
susceptibility of Campylobacter to bile salts.
3) Evaluate the in vivo efficacy of EPIs on the colonization of Campylobacter in
the host using chicken model system.
4) Determine the effect of anti-CmeC antibodies on the susceptibility of C. jejuni
to bile salts.
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3. MATERIALS AND METHODS

Bacterial Strains and Culture Conditions

The key Campylobacter jejuni strains used in this study are listed in Table 1 (all
tables and figures are located in the appendix). Other Campylobacter clinical isolates
tested in this study are described in Table 2. Both C. jejuni 81-176 (a human isolate) and
S3B (a chicken isolate) have been used for the characterization of CmeABC efflux
system in the previous studies (Lin et.al., 2002, 2003, 2005a,b; Luo et.al., 2003, 2005).
All strains were routinely grown in Mueller-Hinton (MH) broth or agar at 42° C under
microaerophilic conditions which were generated using a Campypak gas pack (Oxoid) in
an enclosed jar. When needed, MH media was supplemented with 30 µg/ml of
kanamycin, or appropriate concentrations of ciprofloxacin or erythromycin. All media
were purchased from Difco.

Antimicrobial Stock Preparation

Antimicrobial stocks were prepared by completely dissolving specific
antimicrobial (in powder form) in appropriate solvent. Specifically, tetracycline (10
mg/ml), ampicillin (50 mg/ml), ciprofloxacin (10 mg/ml), cefotaxime (25 mg/ml),
sodium dodecyl sulfate (50 mg/ml), nalidixic acid (100 mg/ml), novobiocin (50 mg/ml),
fusidic acid (50 mg/ml), cetylpyridinium chloride (20 mg/ml) and trisodium phosphate
(10 mg/ml) were solublized in deionized distilled H2O followed by sterilization through
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membrane filtration (0.22 µm filter). Norfloxacin (25 mg/ml) was solublized in acetic
acid while rifampin (25 mg/ml) and erythromycin (25 mg/ml) were dissolved in dimethyl
sulfoxide (DMSO) and ethanol, respectively. The above stock solutions were then
aliquoted into sterile 2 ml tubes and stored in a -20ºC freezer.

Bile salts including cholic acid (32 mg/ml), taurocholic acid (64 mg/ml),
chenodeoxy choic acid (32 mg/ml) and glycocholic acid (32 mg/ml) were freshly
prepared by dissolving the bile salts in MH broth. The solutions were sterilized through
membrane filtration (0.22 µm filter) and used immediately. All bile salts used in this
study are sodium salts, and their pH is approximately 7.0 after solubilization in MH broth
for susceptibility and growth assays.

The antibiotics and other antimicrobials used in this study were purchased from
Sigma Chemical Co. (nalidixic acid, norfloxacin, erythromycin, cefotaxime, rifampicin,
ampicillin, tetracycline, cholic acid, chenodeoxycholic acid, taurocholic acid, glycocholic
acid, cetylpyridinium chloride, trisodium phosphate), ICN Biomedicals Inc
(ciprofloxacin), and Bio-Rad (sodium dodecyl sulfate, ethidum bromide).

Construction of CmeB Isogenic Mutants

C. jejuni 81-176 CmeB isogenic mutant was originally created using EZ::TN
<KAN-2> Tnp Transposome and was used in previous studies (Lin et al., 2002, 2003,
2005 a, b). The cmeB insertional mutation in 81-176 was introduced to S3B by standard
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biphasic natural transformation (Wang and Taylor, 1990) to create JL 141 (Table 1). To
perform natural transformation, genomic DNA was extracted from 9B6 using a Wizard
Genomic Purification Kit (Promega). Wild-type strain S3B cells grown overnight on MH
plates were harvested with MH broth and adjusted to the approximate concentration of 3
x 109 CFU ml-1 (corresponding to OD600 = 0.5). 0.5 ml of S3B cells were then added to
15 ml polypropylene tubes containing 1 ml MH agar and the tubes were incubated 3 h at
42oC under microaerophilic conditions. Following incubation, 1µl of 9B6 genomic DNA
(~ 0.2 µg) was mixed with cells by pipetting up and down. Following another 3 h of
incubation under microaerophiilic conditions, cells were plated on MH plates with
30µg/ml of kanamycin and the plates were incubated at 42° C under microaerophilic
conditions for two days. A single KanR colony was selected, and the insertional mutation
in cmeB in this isolate was confirmed by PCR using a pair of cmeB specific primers ES5
and ERP-2 as described below. Further quick phenotypic confirmation for cmeB
mutation was performed by disk diffusion method. Briefly, wild-type S3B and its
putative isogenic cmeB mutant cells were spread onto MH agar plates. A sterile disk (6
mm wide) was placed in the center and 10µl of 5% cholic acid was placed on disk. Plates
were incubated at 42° C under microaerophilic conditions for two days and the inhibitory
zones were recorded.

Polymerase Chain Reaction (PCR)

PCR was performed in a volume of 50µl containing 200µM concentration of each
of the deoxynucleoside triphosphates, 200nM concentrations of primers, 2.5mM MgSO4,
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50ng of Campylobacter genomic DNA, and 5U of Taq DNA polymerase (Promega).
Cycling conditions varied according to the estimated annealing temperatures of primers
and the expected size of the product. To confirm insertional mutation in cmeB gene in
mutants, primers ES5 (5’- CGATCCCTATGGCTAAATT -3’) and ERP-2 (5’AAAAATTCAAGTTGGTAGCGAAGT -3’) were designed from the sequence of
cmeABC operon in C. jejuni 81-176 (Lin et al., 2002) and used in PCR with genomic
DNA samples from wild-type strains or mutants. To determine if macrolide resistancerelated point mutation occurred in domain V of the 23 S rRNA gene, a 508-bp specific
fragment of 23S rDNA of resistant and sensitive strains were amplified by PCR using
specific primers 23SF (5’- AAGAGGATGTATAGGGTGTGACG -3’) and 23SR (5’AACGATTTCCAACCGTTCTG -3’) (Vacher et al., 2003). A pair of specific primers
MOMPF (5’- ATGAAACTAGTTAAACTTAGTTTA- 3’) and MOMPR (5’GAATTTGTAAAGAGCTTGAAG -3’) were used to amplify Campylobacter major
outer membrane protein gene cmp that is a good target for molecular typing (Huang et al.,
2005). In some PCR reactions, boiling samples were used as template. Briefly, 1ml of
C. jejuni cells are centrifuged for 4 minutes at 10,000 x g and the resulting pellet was resuspended in 100µl sterile deionized distilled water. The tubes containing cell
suspensions were then placed in boiling water for 10 minutes, followed by centrifugation
at speed 10,000 x g for 4 minutes. The supernatant was removed to clean
microcentrifuge tube and used as a DNA template for PCR. The PCR products were run
along with 1kb DNA ladder (Promega) on a 1.0% agarose gel that was stained by
ethidium bromide and visualized by using FluoChem 5500 digital imaging system (Alpha
Innotech).
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Sequence Analysis

The amplified PCR products were purified using the QIAquick PCR Purification
Kit (Qiagen) prior to sequencing. DNA sequencing was carried out using an automated
DNA sequencer (model 377; Applied Biosystems). Sequences were aligned with
Pairwise BLAST at the NCBI website (http://www.ncbi.nih.gov/BLAST/).

Efflux Pump Inhibitors (EPIs)

Efflux pump inhibitor MC-207,110 (Phe-Arg β-naphthyl-amide dihydrochloride)
(Figure 1) is commercially available from Sigma (catalog no. P4157). MC-207,110 is the
first effective EPI targeting RND efflux pumps and was identified by screening a large
synthetic compounds and natural product libraries (Lomovskaya et al., 2001a). Stock
solutions were made using deionized distilled water (dd H2O) to final concentration of 25
mg/ml followed by sterilization through membrane filtration. In addition to MC-207,110,
MC-04,124 (Figure 1) was also used in this study. MC-04,124 is an analogue of MC207,110 and is less toxic in vivo (Renau et al., 2003). The MC-04,124 was kindly
provided by Olga Lomovskaya (MPex Pharmaceuticals, CA). Stock solutions of MC04,124 were made at a concentration of 20 mg/ml using dd H2O and sterilized by
membrane filtration.
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Susceptibility Tests

Minimum inhibitory concentration (MIC) tests were performed to determine the
susceptibility of Campylobacter to a variety of antimicrobials with or without EPI MC207,110. Standard microtiter broth dilution method was used to determine MICs as
described by Jorgensen and Turnidge (2003) with slight modifications. Briefly,
antimicrobials stock solutions were completely thawed, vigorously vortexed and diluted
in MH broth (with or without 10 µg/ml of EPI MC-207,110) to initial testing
concentrations (the highest testing concentration). Then, 240µl of diluted antimicrobial
solution was placed into the wells in the first lane of a 96 well plate (Nunc) with
duplicate for each antimicrobial. 120µl of plain broth was put into the remaining wells
using an 8-channel pipette. Antimicrobial solutions in the first lane were serially diluted
using a 2- fold dilution scheme in which 120µl from the wells in the first lane was
transferred into the wells in the second land and mixed by pipetting up and down five
times. This procedure was repeated for the rest of the wells with the exception of the
wells in the last lane, which were left free of antimicrobials as a positive control. To
prepare inoculum for MIC test, C. jejuni was grown in MH broth to late-log phase (~
8x108 cfu/ml; grown at 42°C for 24-36 h under microaerophilic conditions). The cultures
were then 20-fold diluted in MH broth to make inoculum with appropriate concentration
of 4x107 cfu/ml. 5 µl of the above inoculum was transferred to each well in 96-well plate
using a 12-channel pipette, resulting in a final inoculum of 1.6 x 105 cfu/well. Microtiter
plates were incubated for 2 days under microaerophilic conditions at 42° C. The MIC was
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determined by the lowest concentration of antimicrobial agent that completely inhibited
the growth of Campylobacter.

Checkerboard Titration Assay

To determine if the effect of EPI MC-207,110 on increasing the susceptibility of
C. jejuni to antimicrobials is dose-dependent, checkerboard assays were performed using
96-well plates as described previously (Lomovskaya, et al., 2001a). Representative
antimicrobials erythromycin and cholic acid were tested at 11 concentrations ranging
from 0.004 to 4µg/ml and from 0.03 to 30 mg/ml, respectively. The EPI MC-207,110
was tested at 7 concentrations ranging from 0.25 to16 µg/ml. Briefly, in one 96-well plate
specific antimicrobial was serially diluted from its starting concentration across the rows
as described above for standard MIC tests. The last column was left free of antimicrobial
and the final volume of all wells was 50µl. A second plate was prepared for EPI MC207,110 which was serially diluted in MH broth from its starting concentration down
each column. The last row was left free of the EPI and the final volume of all wells was
50µl. A multi-channel pipet was used to transfer the 50µl in each well of the EPI plate
into the corresponding well in the antimicrobial plate. The final volume in each well was
100µl. The plate was inoculated with one C. jejuni strain (81-176, S3B, 9B6, or JL141)
as described above in Susceptibility Test session. Microtiter plates were incubated for 2
days under microaerophilic conditions at 42° C. Bacterial growth in each well was
recorded and MICs were determined.
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In vitro Selection of Fluoroquinolone(FQ)- and Erythromycin(Ery)-Resistant
Mutants

Two different in vitro selection experiments were conducted to address different
objectives in this study. In the first experiment, FQ-resistant and Ery-resistant mutants
were obtained in vitro and were used to determine if EPI MC-207, 110 can reverse
acquired resistance in these mutants. Briefly, 100µl of wild-type 81-176 or S3B cells
were plated on MH plates and grown overnight at 42° C under microaerophilic
conditions. The fresh cells were then harvested from plates using fresh MH broth. Cell
suspensions were spread on MH agar plates containing antibiotic Ery (8 µg/ml) or
ciprofloxacin (4 µg/ml). Following 2-day incubation under microaerophilic conditions at
42° C, single FQ-resistant or Ery-resistant colony on selective plates were selected and
inoculated in MH broth. The selected antibiotic resistant mutants (detailed in Table 1)
were used for MIC test in MH broth with or whithout EPI MC-207,110. In addition,
cmeB insertional mutation was also transferred to JL157-160 strains by natural
transformation as detailed above, resulting in strains JL161-164 (Table 1). These isogenic
cmeB mutants were also used for testing MIC of Ery in the presence or absence of EPI
MC-207,110.

In the second experiment, the effect of EPI MC-207,110 on the frequency of in
vitro emergence of Ery-resistant and FQ-resistant mutants in C. jejuni was determined.
The cells were prepared as described above. The cells were then centrifuged for 4
minutes at 10,000 rpm and pellets were resuspended in small volume of fresh MH broth.
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100 µl of the highly concentrated C. jejuni suspension was plated onto MH plates
containing specific antibiotic (4 µg/ml of Ery or 4 µg/ml of ciprofloxacin) and onto MH
plates containing both specific antibiotic and MC-207,110 (10 µg/ml). In the mean time,
the C. jejuni suspensions were serially diluted in MH broth (1:10) and plated on plain
MH plates to determine the concentration of the C. jejuni suspension. After a 2-day
incubation at 42°C under microaerophilic conditions, colonies on each plate were
enumerated. Frequencies of emergence of resistant mutants were determined as ratios
between the number of colonies that grew on MH plates containing specific antibiotic
(with or without MC-207,110; expressed as numbers of CFU per ml) to the number of
colonies showing on MH plates without antibiotics or MC-207110.

Effect of EPIs on the Colonization of C. jejuni in Chickens

Two animal challenge experiments were conducted in this study: A) To evaluate
the effect of treatment of EPI (MC-207,110 or MC-004,124) on the colonization of C.
jejuni in chickens; and B) To evaluate the effect of multiple dosing and treatment of MC207,110 on the colonization of C. jejuni in chickens. The experimental design is detailed
in Table 3. C. jejuni strain S3B was chosen for challenge studies based on following
reasons. First, C. jejuni strain S3B was originally isolated from chickens in our
laboratory. This strain has been fully characterized in our laboratory by molecular
methods and its genetic fingerprints are fully known, facilitating the differentiation of this
strain from other isolates (Huang et al., 2005; Luo et al., 2003, 2005; Zhang et al., 2000).
Second, S3B colonizes chickens effectively and has been used in our previous chicken
32

studies (Luo et al., 2003, 2005; Sahin et al., 2003). In addition, in vitro analysis has
demonstrated that EPI MC-207,110 dramatically increased susceptibility of S3B to bile
salts. These features of S3B have made it an ideal strain for the challenge experiments.
For both trials, one-day-old broiler chickens were obtained from Hubbard Hatchery, a
commercial hatchery company in Pikeville, Tennessee. Prior to use, these chickens were
screened for Campylobacter by culturing cloacal swabs, which were plated onto MH agar
plates containing Campylobacter-specific growth supplements (SR084E and SR117E;
Oxoid). All of the birds were negative for Campylobacter. For both experiments, 5-dayold chickens were weighed (~62 g/chick) and all chicks were inoculated via oral gavage
one time with C. jejuni S3B at dose of 105 CFU/chick. In the first experiment, specific
EPI were administered into each chick at appropriate dose 30 min after chickens were
inoculated with C. jejuni S3B (Table 3). In the second experiment, a wider dose range
was used for MC-207,110 (3 mg/kg – 75 mg/kg) and an additional two EPI treatments
were given at 24 h and 48 h post-inoculation. Each group was maintained in a sanitized
wire-floored cage and provided with unlimited access to feed and water. Cloacal swabs
were taken at days 2, 4, 7 and 9 days post-inoculation. Swabs were placed in 1ml MH
broth, briefly vortexed and 100µl suspensions were spread onto MH plates containing
Campylobacter-specific selective supplements. The plates were then incubated for two
days at 42° C under microaerophilic conditions and the number of colonies was counted.
Some of selected colonies were tested by PCR to ensure that the output Campylobacter
populations were the same as the inoculum and that there was no contamination of the
chickens by other sources. The percentage of chickens colonized by C. jejuni and the
shedding level of Campylobacter in chickens colonized by C. jejuni after inoculation and
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treatment were determined. Chi square analysis (SAS 9.1) was used to measure the
significant differences in the percentage of colonized chickens at each time point between
groups. One-way analysis of variance followed by a least-significant difference was
used to calculate the significant differences in shedding level (log transformed). All
animal studies were conducted under IACUC standard protocols (University of
Tennessee IACUC protocol number: 1428).

Preparation of Chicken Intestinal Extracts

Chicken intestinal extracts were prepared from three different sections of the
intestine (duodenum, jejunum and cecum) as described previously (Lin et al., 2003). Six
21-day-old chickens were used for the preparation of chicken intestinal extracts. All
birds tested negative for Campylobacter by culturing cloacal swabs. The intestinal
contents from each section were pooled from six chickens. The same volume of MH
broth was thoroughly mixed with each pool of chicken intestinal extracts, followed by
centrifugation at 10,000 x g at 4 oC for 30 min. The supernatant was carefully pipetted
out and passed through a series of membrane filtrations for sterilization (prefilter, 1.2µm,
0.45µm, and 0.22 µm; Millipore Co.). The sterilized extracts were then aliquoted into 2
ml sterile tubes and stored in -20° freezer.
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Effect of CmeC Antibodies on the Susceptibility of C. jejuni to Bile Salts

Polyclonal rabbit anti-CmeC serum directed against a portion of CmeC (aa 41 to
248 of total 492 aa in length) was produced in a previous study (Lin et al., 2002). Prior to
any assays, both rabbit control serum (pre-immune serum, negative for CmeC) and antiCmeC serum was incubated at 56 oC for 30 min to abolish complement activity.
Susceptibilities of C. jejuni to bile salts in the presence of specific CmeC antibodies or
control antibodies were performed in 96-well microtiter plates (Corning). Prior to assays,
C. jejuni 81-176 was grown for 16 hr at 42oC in MH broth containing sublethal
concentration of bile salt taurochloric acid (2mg/ml) to induce CmeC expression. The
cultures were then washed twice in MH and diluted to approximately 1 x 107 CFU/ml in
MH broth. For the susceptibility assay, the total volume in each well was 250 µl in
which 25 µl of diluted culture and 25 µl specific serum (anti-CmeC serum or control
serum) were inoculated in 200 µl of MH broth containing 4 µg/ml of cholic acid or 200 µl
of chicken intestinal extract. After 6 hr of incubation at 42oC under microaerophilic
condition, 20 µl of bacterial culture were taken and serially diluted in ice-cold MH broth
and plated onto MH agar plates. The number of colony forming units (CFU) was
enumerated after a 2-day incubation under microaerophilic conditions at 42oC. All
assays were done in triplicate. The CFU mean comparisons between treatment groups
were analyzed using Student T test (SAS 9.1).

As a long term effort to quantitatively evaluate specific anti-CmeC IgG on the
susceptibility of C. jejuni to bile salts, the anti-CmeC IgG were purified from the rabbit
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anti-serum by protein G affinity chromatography using ImmunoPure (G) IgG Purification
Kit (Pierce). SDS-PAGE with 12% (wt/vol) polyacrylamide separating gel was used to
determine the purity and molecular mass of purified IgG. The IgG concentration was
measured by Bicinchonic Acid Protein Assay (Pierce).
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4. RESULTS

EPI MC-207,110 Increases the Susceptibility of C. jejuni to Various Antibiotics

As shown in Table 4, the presence of EPI MC-207,110 significantly reduced
MICs of different antimicrobial compounds. Of most interest, the MIC of erythromycin,
the current antibiotic of choice for treating Campylobacter infections, was dramatically
decreased 32-fold in 81-176 and 64-fold in S3B strain in the presence of the EPI. When
C. jejuni 81-176 was grown in MH broth with MC-207, 110, the MICs of
fluoroquinolones were decreased 2-fold (ciprofloxacin) and 4-fold (nalidixic acid); the
MICs of β-lactams (cefotaxime and ampicillin) were decreased 2-fold; the MICs of
rifampin, tetracycline, ethidium bromide, novobiocin and fusidic acid were decreased
1024-fold, 2-fold, 4-fold, 128-fold and 64-fold, respectively (Table 4). Similar
significant MIC reductions were also observed for C. jejuni S3B grown in MH broth
containing MC-207,110 (Table 4). Interestingly, presence of MC-207,110 also
significantly increased susceptibility of both C. jejuni strains to cetylpyridinium chloride
(8-fold MIC reduction), a recently approved food antimicrobial used by the poultry
industry to reduce Campylobacter spp. during processing (Oyarzabal, 2005). However,
MC-207,110 had only moderate or no effect on the susceptibility of C. jejuni to other two
commonly used food antimicrobials trisodium phosphate and sodium hypochlorite (Table
4).
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Effect of MC-207,110 on the Susceptibility of cmeABC Mutants to Various
Antibiotics

Isogenic cmeABC mutants were constructed for MIC test to determine if the
effect of MC-207-110 is primarily mediated by CmeABC efflux pump. As shown in
Figure 2A, we purified genomic DNA from 9B6 (lane 2), an isogenic cmeB mutant of 81176, for natural transformation. The insertional mutation cmeB was successfully
transferred to wild-type S3B strain, resulting in the putative cmeB mutant JL141 with
kanamycin resistance. PCR analysis using cmeB specific primers resulted in ~1.25 kb
fragment for wild-type 81-176 while a larger size fragment (~3.0 kb) in 9B6 was
generated, indicating cmeB gene was interrupted by transposon insertion in mutant 9B6
(Figure 2A). However, the cmeB specific primers did not result in visible bands for both
S3B and JL 141 strains (Figure 2A, lanes 5 and 6), likely due to cmeB sequence
variations between 81-176 and S3B. Since cmeB mutant is hypersusceptible to bile salts
(Lin et al., 2002, 2003), a disk diffusion assay was performed to confirm if JL 141
contained the desired mutation in cmeB and corresponding phenotype change. Following
a 2-day incubation, no inhibition zone was observed for wild-type S3B (Figure 2B) while
putative cmeB mutant JL 141 showed greatly increased sensitivity to cholic acid, as
indicated by a distinct zone of inhibition (diameter of 29 mm) (Figure 2B).

As shown in Table 5, EPI MC-207,110 still resulted in significant MIC reductions
in both cmeB mutants for most antibiotics. However, for many antibiotics, the magnitude
of MIC reduction is smaller than that in wild-type strains (Table 4). For example,
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presence of MC-207,110 in broth led to 128-fold and 512-fold reduction in the MIC of
novobiocin in 81-176 and S3B, respectively (Table 4). When cmeB was knocked out in
81-176 and S3B, MC-207,110 still resulted significant reduction in the MIC of
novobiocin (Table 5) but the magnitude of MIC reduction (4- fold) is much smaller than
that in wild-type parent strains (128- and 512- fold).

Effect of MC-207,110 on the Susceptibility of C. jejuni to Antibiotics is DoseDependent

To determine if the effect of EPI MC-207,110 on reducing MICs of antibiotics
observed above was dose dependent, standard checkerboard assays were performed using
clinically important erythromycin as a representative antibiotic. As shown in Table 6, 8
µg/ml of MC-207,110 led to the most significant reduction of MIC in C. jejuni 81-176
(256-fold) and in S3B (64-fold) compared to the MICs tested in MH broth without the
EPI. With a decrease of MC-207,110 concentration in MH broth for MIC test, the MIC
reduction also declined (Table 6). However, as low as 0.25µg/ml of the EPI in MH broth
still resulted in significant MIC reductions in most strains (Table 6).

MC-207,110 Reversed Acquired Antibiotic Resistance in C. jejuni

To determine if MC-207,110 reversed acquired antibiotic resistance, both Eryresistant and Cipro-resistant mutants were first selected in vitro using wild-type
susceptible strains 81-176 and S3B. As shown in Table 7, presence of MC-207,110 not
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only reduced MICs of Ery in wild-type strain 81-176 and S3B but also resulted in
dramatic MIC reduction in all Ery-resistant mutants (JL154 to JL160) with reduction
range from 16-fold to >64-fold. In other words, in the presence MC-207,110, all Eryresistant phenotypes of mutant strains were reversed to susceptible phenotypes. To
determine if macrolide resistance-related point mutation also occurred in domain V of the
23 S rRNA gene, a specific 508-bp fragment was amplified from each Ery-resistant
mutant and used for sequencing (Figure 3A). Interestingly, sequence analysis showed
that none of the mutants had expected A2230G point mutation, which agrees with recent
finding that spontaneous Ery-resistant C. coli had relatively low MICs (32 to 64 µg/ml)
and lacked the A2230G mutation in the 23S rRNA gene (Kim et al, 2006).

The cmeB mutation was also introduced to Ery-resistant mutants JL157 to JL160,
generating isogenic cmeB mutants (JL161-JL164) for evaluating the role of CmeABC
pump in acquired Ery-resistance (Table 7). As shown in Table 7, an insertional mutation
in cmeB (JL161-164) resulted in significantly lower MIC of Ery in MH broth compared
to their parent strains (Jl157-160). Supplementation of MC-207,110 in MH broth led to
further MIC reductions (4-8 folds) in these cmeB mutants.

MC-207,110 also affected the MIC of Cipro in Cipro-resistant mutants (Table 8).
However, unlike its effect on Ery-resistant mutants, MC-207,110 only reduced the MIC
of Cipro in the mutants with high resistance to Cipro (JL152 and JL153) but had no effect
on the mutants with intermediate resistance (JL150 and JL151).
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MC-207,110 Decreased the Frequency of Emergence of Ery-Resistant C. jejuni

To determine if the presence of MC-207,110 could also reduce the frequency of
emergence of antibiotic resistance in C. jejuni, emergence tests were performed on MH
plates containing specific antibiotic and MC-207,110 using wild-type susceptible strain
81-176 and S3B. When tests were performed with Ery alone, the frequency of
emergence of Ery resistance was approximately 10-8 level in both strains (Table 9).
However, when plates were supplemented with 10 µg/ml of MC-207,110, no single Eryresistant colony emerged on the plates and the frequency was less than 1.6 X10-10 in 81176 and 5 X 10-11 in S3B (Table 9). With respect to FQ, presence of MC-207,110 did not
result in significantly decreased frequency of emergence of Cipro-resistant C. jejuni
mutants. The frequency of emergence of Cipro-resistant C. jejuni was approximately 2.1
X10-8 in vitro.

MC-207,110 Increased Susceptibilities of Various Clinical Campylobacter Isolates to
Ery

To determine if MC-207,110 not only increases the susceptibilities of clinical
strain C. jejuni 81-176 and S3B but also reduces the MICs for other clinical isolates from
various sources, MICs of Ery were measured on 57 clinical isolates of different origins
(Table 2). The EPI significantly increased the susceptibilities of all clinical isolates to
Ery (Figure 4). MIC reduction was as high as 512-fold (Figure 4). The majority of the
isolates displayed a 4- to 32- fold reduction in the MIC of Ery in the presence of EPI MC41

207,110 (Figure 4). Importantly, five isolates were highly resistant to Ery and displayed
significant Ery MIC reductions ranging from 8- fold to 62- fold.

EPI MC-207,110 Increases the Susceptibility of Campylobacter jejuni to Various Bile
Salts

As shown in Table 10, the MICs of detergent SDS and all four bile salts were
dramatically decreased in the presence of the EPI. The MIC reduction ranged from 16fold to 512-fold. As expected, insertional mutation in cmeB drastically decreased MICs
of bile salts and detergent in both mutants in MH broth (Table 11). Although presence of
MC-207,110 resulted in further MIC reduction for both the two cmeB mutants, the
magnitude of MIC reduction for bile salts (2- to 32-fold) was much smaller than that
observed for wild-type strains (Table 10 and Table 11). The checkerboard titration assay
also demonstrated the dose effect of MC-207,110 on increasing susceptibility of C. jejuni
to the bile salt cholic acid (Table 12).

We also determined the effect of another EPI MC-04,124 on the susceptibilities of
C. jejuni to different antimicrobials including four bile salts. The EPI MC-04,124
resulted in comparable MIC reductions for all antimicrobials as those for MC-207,110
(Table 4 and 10). However, higher concentrations of MC-04,124 (50 µg/ml) was used in
MIC test when compared to MC-207,110 (10 µg/ml), indicating in vitro activity of MC04,124 is not as potent as MC-207,110.
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EPIs Reduced Colonization of C. jejuni in Chickens

As shown in Figure 5, colonization levels of C. jejuni in EPI treatment groups
were lower than that in the control group. Specifically, the control group without EPI
treatment had a 60% colonization rate 2 days post inoculation. However, there was no
colonization in any chicken in the group treated one time with low-dose of MC-207,110
and high-dose of MC-04,124 at 2 days postinoculation (Figure 5). EPI MC-04,124
treatment doses also resulted in lower colonization levels compared to the control group
(Figure 5). As the study continued, the differences between treatment and control groups
lessened (Figure 5), most likely due to horizontal transmission of C. jejuni among
chickens within a group and the single administration of EPI at day 0. Surprisingly, we
observed a reversed dose effect for MC-207,110 in this experiment (Figure 5). To further
define the dose effect of MC-207,110 in vivo and examine the effect of EPI
administration regimen, we conducted another chicken experiment with modification of
using three different EPI dose and administered EPI for three times. The second chicken
study (Figure 6A) also showed that MC-207,110 reduced the percentage of chickens
colonization by C. jejuni S3B when compared to the control group (90%). Similar to the
finding in the first chicken study (Figure 5), the highest dose of MC-207,110 resulted in
highest percentage of colonization among three EPI-treatment groups (Figure 6A).
Despite MC-207,110 were administered for three consecutive days, inhibition of
colonization of C. jejuni by MC-207,110 lessened throughout the study and by day 9
postinoculation C. jejuni S3B colonized 80 – 90 % of chickens for all groups. Shedding
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levels of chickens colonized with Campylobacter were also evaluated and no significant
difference was observed among four groups.

To confirm that the isolates recovered from the experimental chickens were
derived from the inoculated S3B, the cmp gene encoding the major outer membrane
protein was PCR amplified with representative Campylobacter isolates obtained from the
chickens. The sequence data showed that the cmp sequences were identical to that of
S3B, indicating that the output Campylobacter populations was the same as the inoculum
and there was no contamination of chickens by other sources.

Effect of Anti-CmeC on the Growth of C. jejuni

To determine if the function of CmeABC can also be inhibited by immune
intervention, the effect of anti-CmeC serum on the C. jejuni growth in bile-containing
media was investigated. As shown in Figure 7, compared to the growth in the presence
of control serum, supplementation of anti-CmeC serum in MH broth containing sublethal
concentrations of bile salt cholic acid resulted in moderate but significant growth
reduction (~ 0.65 log unit), suggesting anti-CmeC antibodies specifically inhibit the
function of CmeABC pump and increased susceptibility of C. jejuni to bile salts.
Despite above difference resulting from CmeC antibodies, anti-CmeC serum did not led
to significant growth reduction of C. jejuni in chicken intestinal extracts (data not
shown).
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Purification of Anti-CmeC IgG

To further define the role of anti-CmeC IgG on the function of CmeABC pump in
the future, we initiated the purification of rabbit anti-CmeC IgG using protein G affinity
chromatography. As shown in Figure 8, highly purified anti-CmeC IgG were successfully
obtained using protein G affinity chromatography. Most of the antibodies were eluted in
the fourth fraction (lane 6 in Figure 8B) with the highest absorbance (2.22) at 280 nm.
Based on BCA assays, a total of ~10 mg of IgG were purified from 2.5 ml of crude rabbit
anti-CmeC serum.
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5. DISCUSSION

The results of this study clearly demonstrate the feasibility of developing a
CmeABC efflux pump- based intervention strategy against Campylobacter. This
conclusion is supported by the following evidence. First, EPI MC-207,110 greatly
potentiated the efficacy of various antibiotics against C. jejuni, primarily mediated by
inhibition of CmeABC efflux pump. Specifically, MC-207,110 dramatically increased
the susceptibilities of C. jejuni to structurally unrelated antibiotics including the clinically
important macrolide Ery (Table 4 and 5) in a dose-dependent manner (Table 6). MC207,110 also effectively inhibited the CmeABC efflux pump in drug-resistant C. jejuni
strains and significantly reversed acquired resistance (Table 7 and 8; Figure 4). More
importantly, presence of MC-207,110 drastically reduced the frequency of emergence of
macrolide-resistant mutants in C. jejuni (Table 9). Second, inhibition of the CmeABC
efflux system by EPI MC-207,110 made C. jejuni strains hypersusceptible to bile salts,
which can act as bactericidal antimicrobials in intestine (Tables 10 and 11), and
consequently reduced C. jejuni colonization in the host, as shown by this experiment
using a chicken challenge model system (Figure 5). Finally, antibodies directed against
partial region of outer membrane protein CmeC also displayed an inhibitory effect on the
function of CmeABC pump and decreased the survival of C. jejuni in the presence of bile
salts (Figure 7). Together, these findings provide compelling evidence that inhibiting C.
jejuni CmeABC efflux pump by EPIs or specific CmeC antibodies may be a novel
approach to combat antibiotic resistance and prevent and control Campylobacter
infection in humans and animal reservoirs.
46

EPI MC-207,110 has been demonstrated to be effective against a variety of Gramnegative bacteria (Chollet et al., 2004; Hasdemir et al., 2004; Lomovskaya et al., 2001a ;
Mamelli et al., 2003,2005; Saenz et al., 2004) since it was first discovered by
Lomovskaya et al. (2001a). Unlike those studies in which the efficacy of the EPI was
only investigated with respect to very limited antimicrobials, our study comprehensively
examined the effect of EPI MC-207,110 to a wide spectrum of structurally unrelated
antimicrobials. In conjunction with the use of genetic approaches for identified
CmeABC efflux pump, findings from this study clearly indicated that inhibition of the
CmeABC efflux system greatly increased susceptibility of C. jejuni to different
antibiotics including a macrolide (erythromycin) and FQ, the major drug of choice for
treating human campylobacteriosis. Findings from this study also revealed two unique
groups of antimicrobials that are also affected by EPI, which has never been reported in
other bacteria. The first group of antimicrobials is bile salts that are the substrate of
CmeABC efflux pump and are naturally present in the intestine forming a barrier to limit
enteric pathogen infections (Lin et al., 2003, 2005b). The unique role of CmeABC in bile
resistance and the potent effect of EPI MC-207,110 on increasing susceptibility of
Campylobacter to bile salts in vitro and in vivo strongly suggest that EPI could be
directly used as therapeutic intervention of Campylobacter infection. The second group
of novel antimicrobials consists of commercial food antimicrobials commonly used by
the poultry industry to reduce Campylobacter spp. during processing (Oyarzabal, 2005).
We observed that the presence of MC-207,110 significantly decreased the MIC of two
food antimicrobials (Table 4), particularly for cetylpyridinium chloride, a recently
approved food antimicrobial. This finding suggests that EPI may be also used as a novel
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agent in post-harvest food safety to potentiate commonly used food antimicrobials during
processing. However, EPI did not potentiate the efficacy of sodium hypochlorite (Table
4), a commonly used antimicrobial in food processing. The mode of action of specific
food antimicrobials may determine its sensitivity to EPI. For example, disruption of cell
membrane is a suggested mechanism for cetylpyridinium chloride and trisodium
phosphate (Oyarzabal, 2005) and notably, is also a mechanism for detergents and bile
salts that are the substrates of CmeABC efflux pump (Lin et al., 2002, 2003, 2005b).

Macrolides such as Ery are considered the antibiotic of choice for treating
Campylobacter infections because FQs are losing effectiveness in clinical treatments due
to the widespread resistance of Campylobacter to this class of antibiotics (Enberg et al.,
2001; Smith et al., 1999). Unfortunately, Campylobacter resistance to Ery is also on the
rise (Enberg et al., 2001). Therefore, in this study we placed extensive efforts on
determining the effect of EPI MC-207,110 on Ery-resistance in C. jejuni and our findings
strongly suggest that EPI is a novel agent for fighting Ery resistance in C. jejuni. We
have demonstrated that inhibition of CmeABC efflux pump (i) decreased the level of
intrinsic Ery resistance significantly, (ii) revered acquired Ery resistance, and (iii)
resulted in a decreased frequency of emergence of C. jejuni mutants that are resistant to
Ery. A similar effect resulting from MC-207,110 was observed by Lomovskaya (2001a)
for FQ-resistance in P. aeruginosa. Although MC-207,110 has also been used to study
Ery-resistance in Campylobacter by other groups recently (Gibreel et al., 2005; Mamelli
et al., 2003, 2005), our study provided much more comprehensive information of the
effect of MC-207,110 on the function of CmeABC efflux pump and on the development
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of Ery-resistance in C. jejuni. In particular, to test the effect of EPI on Ery resistance in
Campylobacter isolates, we used standard broth dilution method instead of disk diffusion
method in which EPI MC-207,110 was supplemented in agar plates in other reports
(Gibreel et al., 2005; Mamelli et al., 2003, 2005). Disk diffusion method is not a standard
MIC test for Campylobacter and is suitable for providing qualitative results but not for a
good quantitative result. However, the broth dilution method is a more reliable reference
method for susceptibility testing and provides better qualitative results than disk diffusion
methods (Jorgensen and Turnidge, 2003). Furthermore, to fully determine the interaction
between EPI MC-207,110 and efflux pumps in all C. jejuni cells in culture, addition of
EPI MC-207,110 in liquid MH broth medium in our study is a better assay system than
the supplementation of the EPI in agar plates, as described by Gibreel et al.(2005) and
Mamelli et al.(2003, 2005). Because of these methodological differences, findings from
our study demonstrated that presence of MC-207,110 greatly reduces the MIC of Ery in
all Ery-sensitive and Ery-resistant Campylobacter strains, which is in contrast of recent
observations that the pattern of most Ery resistant C. jejuni isolates was not affected by
MC-207,110 (Gibreel et al., 2005; Mamelli et al., 2005). Together, our study
demonstrated that EPI is an attractive antimicrobial agent to combat increasing antibiotic
resistance in Campylobacter and significantly potentiates the efficacy of currently
available antimicrobial agents. The in vivo efficacy of EPI on antibiotic resistance (e.g.
Ery-resistance) in Campylobacter needs to be investigated in the future.

Previous studies indicated that CmeABC is a primary MDR efflux pump
contributing to antibiotic resistance in C. jejuni ( Akiba et al., 2006; Ge et al., 2005; Lin
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et al, 2005c). According to whole genome analysis (Lin et al., 2005c), there are only two
RND-type efflux pumps in C. jejuni: CmeABC and CmeDEF. Recently, CmeDEF has
been characterized and found to play a minor role in contributing resistance to various
antimicrobials including Ery (Pumbwe et al., 2005; Akiba et al., 2006). Notably, in this
study, the EPI still resulted in further MIC reductions in isogenic cmeB mutants for most
antimicrobials although the magnitude of MIC reductions was smaller (Table 5, 6, 11,
12), which suggested that, in addition to CmeABC efflux system, other unknown efflux
system(s) also contributed to Campylobacter resistance to antimicrobials including Ery.
Ge et al. (2005) has made isogenic mutants of seven putative efflux pumps in addition to
CmeABC and CmeDEF and evaluated the role of these efflux pumps in antibiotic
resistance. Those investigators observed that CmeABC is the only efflux system that
influences antimicrobial resistance in Campylobacter. Bioinformatics analysis revealed a
total 13 drug efflux systems in C. jejuni, including two RND-type systems (CmeABC
and CmeDEF),four putative MFS efflux pumps, four putative SMR type efflux pumps,
one putative ABC type efflux pump, and two putative MATE (Lin et al., 2005c). It is
likely that other unidentified gene loci (e.g. Cj1687, Cj1375 and Cj1187c) contribute to
C. jejuni resistance to clinically important antibiotics, particularly Ery. We have initiated
construction of isogenic mutants of unidentified efflux pumps and will determine MICs
of various antibiotics for those mutants. We will also reevaluate all efflux pumps studied
by Ge et al (2005) using standard broth dilution method rather than agar dilution method
used in Ge’s study (2005) because agar dilution method may not be as sensitive as broth
dilution to differentiate small MIC difference with respect to specific antibiotics, such as
Ery (Personal communication with Dr. Zhang, Iowa State University). After completing
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above studies, we anticipate identifying and characterizing other efflux system(s)
involved in Ery resistance in C. jejuni.

One striking and unique feature of CmeABC is its essential role in bile resistance
and in vivo colonization (Lin et al., 2003). Recent findings (Lin et al., 2005b) also
demonstrated that CmeABC efflux pump is dramatically induced by bile salts, further
highlighting the role of CmeABC in pathogenesis and supporting the hypothesis that the
bile resistance is a natural function of CmeABC. This notion is also supported by a
recent study (Stintzi et al., 2005) in which expression of cmeABC was found to be highly
up-regulated (up to 300-fold) in rabbit ileal loops. These unique features of CmeABC
make the EPI application even more appealing. Inhibition of CmeABC efflux pump by
EPI may directly increase the susceptibility of C. jejuni to in vivo bile salts, consequently
decreasing the colonization level of Campylobacter in intestine. In this study, presence
of MC-207,110 resulted in dramatic MIC reduction (up to 512-fold) for various bile salts
in C. jejuni strains (Table 10). The reductions in MICs of bile salts are primarily
mediated by the CmeABC efflux pump (Table 11). Theses findings clearly support the
feasibility of using EPI directly as a therapeutic agent against Campylobacter. In E. coli
and Salmomella, the AcrAB-TolC efflux pump (a homolog of the CmeABC pump) also
contributes to bile resistance and inducible by bile salts (Prouty et al., 2004; Rosenberg et
al., 2003). Thus, it is likely that inhibiting bacterial efflux of bile salts with EPIs may be
a general approach for developing therapeutic measures for enteric pathogens. However,
the effect of EPI in other enteric pathogens may not be as significant as that observed for
C. jejuni because expression of AcrAB-TolC pump in E. coli and Salmonella was only
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moderately induced by bile salts and the magnitude of MIC reduction in bile due to the
mutation in pump is much smaller in E. coli and Salmonella than that in Campylobacter
(Prouty et al., 2004; Rosenberg et al., 2003).

From the standpoint of practical application, it is important to ensure that the EPIs
not only work well in vitro, but also in vivo, where numerous confounding factors may
affect EPI. MC-207,110 and its derivatives have been evaluated for in vivo toxicity using
mouse model system (Renau et al., 2003). When administered via intravenous (iv) bolus
injection, MC-207,110 displayed appreciable toxic effects (minimum dose causing
lethality to > 66% of the animals tested is < 25 mg/kg). However, a compelling
derivative MC-04,124 was less toxic in rodents (Minimum dose causing lethality to >
66% of the animals tested is >150 mg/kg) (Renau et al., 2003). It has been observed that
MC-207,110 was not stable in serum but MC-04,124 displayed high stability in serum
(Personal communication with Dr. Olga Lomovskaya). Both MC-207,110 and MC04,124 were used for evaluation of in vivo efficacy of EPI using chicken challenge model
in this study. Although the EPI was administered to chickens via route (oral delivery)
different from that used in mice (iv) (Renau et al., 2003) in the first chicken study, a dose
of 25 mg/kg and 150 mg/kg was chosen as highest dose for EPI MC-207,110 and MC04,124, respectively (Table 3). Results showed that both MC-207,110 and MC-04,124
reduced the percentage of colonization of chickens by C. jejuni S3B on day 2 post
inoculation when compared to control animals, regardless of high or low dose. It was
pleasantly surprising to find that MC-207,110 also displayed inhibitory effect on C. jejuni
colonization, which indicates that this EPI is stable and functional in the intestinal tract.
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In addition, data also indicated that in vivo toxicity of EPI also depends on administration
route. Both EPIs were administered orally to chickens in this study and none of chickens
treated with EPI (regardless of the dose) died throughout the study. It is possible that
physiological factors of gastrointestinal tract were responsible for the chickens being able
to tolerate high doses of EPIs. The major limitations of the first chicken study were the
small number of chickens used in each group and that EPI was only administered a single
time to chickens following inoculation of C. jejuni. In the second chicken experiment,
each group contained 9 or 10 chickens and three different EPI doses (3 mg/kg, 15 mg/kg,
and 75 mg/kg for MC-207,110) were administered for three consecutive days following
inoculation of C. jejuni. However, MC-207,110 did not exert further reduction on the
colonization of C. jejuni in chickens throughout the study following three consecutive
EPI treatments (Figure 6). It is likely that MC-207,110 is effective when it is in contact
with Campylobacter in the upper and middle sections of the chicken intestinal tract, such
as duodenum and jejunum, in the first day of inoculation. However, after being
inoculated into chicks, C. jejuni gradually established long-term colonization in two ceca,
the predominant site for Campylobacter colonization in chickens that are immediately
after long small intestine and before cloaca. Thus, MC-207,110 may lose its efficacy
after it passes through long small intestine and reaches the cecum, possibly due to
degradation or binding by host factors. We also consistently observed that high dose of
MC-207,110 treatments led to increased C. jejuni colonization compared to low dose,
suggesting that high dose of EPI MC-207,110 may affect the physiology of chicken
intestine and promote C. jejuni colonization. Overall, our chicken study strongly
indicated that inhibition of Campylobacter efflux pump by EPIs is a potential mean for
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therapeutic intervention to reduce colonization of C. jejuni in human and animal
reservoirs. To develop clinically useful EPI compound, more studies using new lead
series in conjunction with pharmacokinetics/pharmacodynamic analysis are needed in the
future.

Several key issues (e.g. toxicity, in vivo stability, production cost) challenge the
clinical application of EPIs. Thus, alternative ways to inhibit CmeABC efflux pump
should also be explored. Since CmeC is inducible in vivo and is an essential OMP
component of CmeABC efflux pump, anti-CmeC antibodies may function similarly to
EPI in inhibiting CmeABC pumps in C. jejuni, as observed in this study. Immune
intervention by targeting CmeC may be an alternative way to inhibit the CmeABC efflux
pump and avoid problems with EPI. To test this hypothesis, we examined the effect of
anti-CmeC peptide antibodies on the susceptibility of C. jejuni 81-176 to cholic acid, a
representative bile salt. As shown in Fig. 7, anti-CmeC antibodies are only directed
against a portion of CmeC (aa 41to 248 of total 492 aa in length) (Lin et al., 2002). When
compared to the growth in the presence of control serum (pre-immune serum, negative
for CmeC), supplementation of anti-CmeC serum in MH broth containing sublethal
concentration of cholic acid resulted in moderate but significant growth reduction (~ 0.6
log unit), suggesting anti-CmeC antibodies specifically inhibit the function of CmeABC
efflux pump and increase the susceptibility of C. jejuni to bile salts. The inhibitory effect
of the serum is not attributed to complement because both sera were inactivated at 56oC
for 30 min prior to use to abolish complement activity. Since CmeC antibodies only
target a partial fragment of CmeC that may only contain partial protective epitopes, the
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antibodies against full CmeC antigenic structure likely exerts a more significant
inhibitory effect on the Campylobacter grown in the presence of bile salts. Findings of
this study plus other compelling evidences, reported recently (Lin et al., 2003, 2005 ab;
Stintzi et al., 2005) strongly suggest that CmeC could be a novel subunit vaccine against
Campylobacter. More excitingly, since CmeC is an essential component in CmeABC
efflux pump that contributes Campylobacter resistance to clinically important antibiotics,
immunization of host animals with CmeC subunit vaccine may enhance the activity of
clinical antibiotics against C. jejuni and CmeC may represent the first vaccine that can
combat antibiotic resistance in bacteria.
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Table 1. Key Campylobacter jejuni strains used in this study.

a

Strain

Descriptiona

81-176
S3B
9B6
JL 141
JL 150
JL 151
JL 152
JL 153
JL 154
JL 155
JL 156
JL 157
JL 158
JL 159
JL 160
JL 161
JL 162
JL 163
JL 164
JL 187
JL 188

Wild-type; isolated from human
Wild-type; isolated from chicken
81-176 derivative; cmeB::kan
S3B derivative; cmeB::kan
81-176 derivative; in vitro selected Cipro-resistant mutant
81-176 derivative; in vitro selected Cipro-resistant mutant
81-176 derivative; in vitro selected Cipro-resistant mutant
81-176 derivative; in vitro selected Cipro-resistant mutant
S3B derivative; in vitro selected Ery-resistant mutant
S3B derivative; in vitro selected Ery-resistant mutant
S3B derivative; in vitro selected Ery-resistant mutant
81-176 derivative; in vitro selected Ery-resistant mutant
81-176 derivative; in vitro selected Ery-resistant mutant
S3B derivative; in vitro selected Ery-resistant mutant
S3B derivative; in vitro selected Ery-resistant mutant
JL 157 derivative; cmeB::kan
JL 158 derivative; cmeB::kan
JL 159 derivative; cmeB::kan
JL 160 derivative; cmeB::kan
S3B derivative; in vitro selected Ery-resistant mutant
S3B derivative; in vitro selected Ery-resistant mutant

Source or
Reference

Cipro: ciprofloxacin
Ery: erythromycin
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Black et al., 1988
Luo et al., 2003
Lin et al., 2002
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study
This Study

Table 2. Campylobacter clinical isolates used in this study
Strain
CJ 1
CJ 2
CJ 3
CJ 4
CJ 5
CJ 6
CJ 7
CJ 8
CJ 9
CJ 10
CJ 11
CJ 12
CJ 13
CJ 14
CJ 15
CJ 16
CJ 17
CJ 18
CJ 19
CJ 20
CJ 21
CJ 22
CJ 23
CJ 24
CJ 25
CJ 26
CJ 27
CJ 28
CJ 29

Sourcea
Fecal swab
Fecal slurry
Fecal slurry
Water from lagoon
Water from lagoon
Water from lagoon
Water from lagoon
Water from lagoon
Water from lagoon
Calf fecal swab
Calf fecal swab
Fecal slurry
Fecal slurry
Fecal slurry
Water from lagoon
Water from lagoon
Bird dropping
Bedding
Floor
Bedding
Bedding
Fecal slurry
Fecal slurry
Fecal slurry
Water from lagoon
Calf fecal swab
Calf fecal swab
Bedding
Bedding

Strain
CJ 30
CJ 31
CJ 32
CJ 33
CJ 34
CJ 35
CJ 36
CJ 37
CJ 38
CJ 39
JL 10
JL 12
JL 20
JL 21
JL 22
JL 25
JL 36
JL 78
JL 88
JL 93
JL 95
JL 114
JL 115
JL 116
JL 117
JL 118
JL 170
JL 171

a

Sourcea
Feed
Water from lagoon
Water from lagoon
Water from lagoon
Water from lagoon
Water from lagoon
Water from lagoon
Floor
Floor
Water from lagoon
Human
Bovine
Swine (C. coli)
Swine (C. coli)
Swine (C. coli)
Swine (C. coli)
Chicken
Human
Swine
Human
Ovine
Human
Human
Chicken
Chicken
Chicken
Turkey (C. coli)
Turkey (C. coli)

Strains CJ 1 to CJ 39 were isolated from dairy farms in east Tennessee (kindly provided
by Dr. Steve Oliver, University of Tennessee). If not specified, all isolates are
Campylobacter jejuni.
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Table 3. Experiment design of the chicken studies (experiments A and B)
Expt

group

EPI usage/name

EPI Dose
(mg/kg)

EPI treatmenta

# per
Group

A

1 (control)
2
3
4
5
1 (control)
2
3
4

No
Yes/MC-207,110
Yes/MC-207,110
Yes/MC-004,124
Yes/MC-004,124
No
Yes/MC-207,110
Yes/MC-207,110
Yes/MC-207,110

N/A
25
5
150
30
N/A
75
15
3

N/A
Single treatment: 30
min after C. jejuni
inoculation

5
7
5
6
5
10
10
10
9

B

a

N/A
Three treatments: 30
min, 24 h, 48 h after
C. jejuni inoculation

Five-day-old chickens were inoculated with 105 CFU of C. jejuni S3B via oral gavage,
followed by oral administration of EPI.
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Table 4. Susceptibilities of wild-type C. jejuni strains to antimicrobials in MH broth
with or without efflux pump inhibitor MC-207,110
Antimicrobial
Minimum Inhibitory Concentration (µg/ml)
C. jejuni 81-176
C. jejuni S3B
a
MH
MH + MC
MH
MH + MCa
Ciprofloxacin
0.063
0.031 (2)
0.125
0.125 (-)
Nalidixic Acid
8
2 (4)
8
2 (4)
Erythromycin
0.125
0.004 (32)
0.5
0.009 (64)
Ampicillin
1
0.5 (2)
16
4 (4)
Cefotaxime
0.125
0.063 (2)
8
2 (4)
Rifampin
128
0.125 (1024)
128
0.063 (2048)
Tetracycline
0.063
0.031 (2)
32
0.063 (512)
Ethidium Bromide
0.25
0.063 (4)
0.5
0.25 (2)
Fusidic Acid
128
2 (64)
512
2 (256)
Novobiocin
16
0.125 (128)
64
0.125 (512)
Cetylpyridinium Chloride
2
0.25 (8)
2
0.25 (8)
Trisodium Phosphate
12,500
12,500 (-)
25,000
6,250 (4)
Sodium Hypochlorite
62.5
62.5 (-)
15.6
15.6 (-)
a

The numbers in parentheses indicate the fold reductions in MICs for C. jejuni strain
grown in MH broth containing 10 µg/ml of EPI MC-207,110 (MH + MC) compared to
growth in plain MH broth (MH). “-” represents no observed MIC difference.
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Table 5. Susceptibilities of cmeB isogenic mutants to antimicrobials in MH broth with
or without efflux pump inhibitor MC-207,110
Antimicrobial

Ciprofloxacin
Nalidixic Acid
Erythromycin
Ampicillin
Cefotaxime
Rifampin
Tetracycline
Ethidium Bromide
Fusidic Acid
Novobiocin

Minimum Inhibitory Concentration (µg/ml)
81-176, cmeB::kan
S3B, cmeB::kan
a
MH
MH+ MCa
MH
MH+ MC
0.031
0.016 (2)
0.031
0.156 (2)
2
1 (2)
2
1 (2)
0.016
0.004 (4)
0.063
0.002 (32)
0.125
0.031 (4)
4
0.5 (8)
0.031
0.016 (2)
0.063
0.016 (4)
8
0.016 (512)
1
0.004 (256)
0.031
0.031 (-)
8
4 (2)
0.25
0.031 (8)
0.031
0.031 (-)
0.125
0.031 (4)
0.125
0.063 (2)
0.063
0.016 (4)
0.063
0.016 (4)

a

The numbers in parentheses indicate the fold reductions in MICs for C. jejuni strain
grown in MH broth containing 10 µg/ml of EPI MC-207,110 (MH + MC) compared to
growth in plain MH broth (MH). “-” represents no observed MIC difference.
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Table 6. Effects of EPI MC-207,110 combined with erythromycin against C. jejuni
at various concentrations
Strain

Genotype

81-176
wild-type
9B6 81-176, cmeBS3B
wild-type
JL141
S3B, cmeB-

Erythromycin MIC reduction (n-fold) in the presence of
MC-207,110 at a concentration (µg/ml) of:
0
0.25
0.5
1
2
4
8
16
1
4
8
32
64
64
256
NA
1
2
2
4
4
16
NA
NA
1
1
2
4
8
32
64
NA
1
2
4
4
8
16
NA
NA
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Table 7. Susceptibilities of erythromycin-resistant (EryR ) C. jejuni strains to
erythromycin in the presence of efflux pump inhibitor MC-207,110 or absence of
functional CmeABC efflux pump
Strain
C. jejuni 81-176
JL 157
JL158
C. jejuni S3B
JL 154
JL 155
JL 156
JL159
JL160
JL 161
JL 162
JL 163
JL 164

MIC of erythromycin (µg/ml)

Genotype
wild-type
81-176 derivative, EryR
81-176 derivative, EryR
wild-type
S3B derivative, EryR
S3B derivative, EryR
S3B derivative, EryR
S3B derivative, EryR
S3B derivative, EryR
JL 157 derivative; cmeB::kan
JL 158 derivative; cmeB::kan
JL 159 derivative; cmeB::kan
JL 160 derivative; cmeB::kan

a

MH

MH + MC a

0.125
0.5
4
0.5
2
2
2
16
4
0.063
0.063
0.25
0.125

0.004 (32)
<0.031 (>16)
0.125 (32)
0.009 (64)
<0.031 (>64)
<0.031 (>64)
<0.031 (>64)
0.25 (64)
0.125 (32)
0.008 (8)
0.002 (32)
0.031 (8)
0.031 (4)

The numbers in parentheses indicate the fold reductions in MICs for C. jejuni strain
grown in MH broth containing 10 µg/ml of EPI MC-207,110 (MH + MC) compared to
growth in plain MH broth (MH).
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Table 8. Susceptibilities of ciprofloxacin-resistant C. jejuni strains to ciprofloxacin
in the presence of efflux pump inhibitor MC-207,110
MIC of erythromycin (µg/ml)

Strain

Genotype

C. jejuni 81-176
JL 150
JL 151
JL 152
JL 153

wild-type
81-176 derivative, CiproR
81-176 derivative, CiproR
81-176 derivative, CiproR
81-176 derivative, CiproR

a

MH

MH + MC a

0.063
8
8
32
16

0.031 (2)
8 (-)
8 (-)
16 (2)
8 (2)

The numbers in parentheses indicate the fold reductions in MICs for C. jejuni strain
grown in MH broth containing 10 µg/ml of EPI MC-207,110 (MH + MC) compared to
growth in plain MH broth (MH).
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Table 9. Effect of presence of EPI MC-207,110 (10 µg/ml) on the frequency of
emergence of erythromycin-resistant mutants in C. jeuni.
C. jejuni strain Erythromycin MIC Frequency of Erythromycin-resistant mutants
(µg/ml)
(MH agar plates + 4 µg/ml of Erythromycin)
MC-207,110 (−)a
MC-207,110 (+) a
81-176
0.125
1.7 x 10-8
<1.6 x 10-10
S3B

a

8 x 10-8

0.5

The data represent the mean from two treatments.
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<5 x 10-11

Table 10. Susceptibilities of wild-type C. jejuni to detergent and various bile salts in
the presence and absence of EPI
Antimicrobial
Minimum Inhibitory Concentration (µg/ml)
C. jejuni 81-176
C. jejuni S3B
MH
MH + MCa
MH
MH + MCa
Sodium Dodecyl Sulfate
256
4 (64)
256
4 (64)
Cholic Acid
4,000
250 (16)
8,000
250 (32)
Taurocholic Acid
64,000
125 (512)
64,000
500 (128)
Chenodeoxy Cholate
4,000
62.5 (64)
8,000
125 (64)
Glychocholate
32,000
250 (128)
32,000
250 (128)
a

The numbers in parentheses indicate the fold reductions in MICs for C. jejuni strain
grown in MH broth containing 10 µg/ml of EPI MC-207,110 (MH + MC) compared to
growth in plain MH broth (MH). “-”represents no observed MIC difference.
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Table 11. Susceptibilities of cmeB isogenic mutants of C. jejuni to detergent and
various bile salts in the presence and absence of EPI
Antimicrobial
Minimum Inhibitory Concentration (µg/ml)
81-176, cmeB::kan
S3B, cmeB::kan
MH
MH + MCa
MH
MH + MCa
Sodium Dodecyl Sulfate
64
1 (64)
128
4 (32)
Cholic Acid
125
15.625 (8)
250
31.25 (8)
Taurocholic Acid
1000
31.25 (32)
1000
62.5 (16)
Chenodeoxy Cholate
15.6
7.8 (2)
31.3
15.6 (2)
Glychocholate
1000
125 (8)
1000
250 (4)
a

The numbers in parentheses indicate the fold reductions in MICs for C. jejuni strain
grown in MH broth containing 10 µg/ml of EPI MC-207,110 (MH + MC) compared to
growth in plain MH broth (MH).
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Table 12. Effects of EPI MC-207,110 combined with cholate against C. jejuni at
various concentrations

Strain

Genotype

81-176
S3B
JL141

wild-type
wild-type
S3B, cmeB-

Cholate MIC reduction (n-fold) in the presence of
MC-207,110 at a concentration (µg/ml) of:
0
0.25
0.5
1
2
4
8
16
1
1
1
1
8
16
64
NA
1
1
1
2
4
16
64
NA
1
1
1
1
2
4
NA
NA
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MC-207,110

MC-04,124

Figure 1. Structures of efflux pump inhibitors used in experiments. MC-207,110 is
available from Sigma and the formal name is Phe-Arg β-naphthyl-amide dihydrochloride.
MC-207,110 was used throughout all in vitro experiments and also the in vivo
experiment; MC-04,124 was primarily used for the in vivo experiment.
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(A)

kb

1

2 3

4

5

6

10,000

3.0 kb
2,000

1.25 kb
1,000
500
250

(B)

JL 141 (cmeB-)

wild-type S3B

Figure 2. Construction and confirmation of isogenic cmeB mutant. (A)
Construction of cmeB mutant and PCR confirmation. Purified genomic DNA
from 9B6 (lane 2) was used for natural transformation. cmeB specific primers
ES5 and ERP-2 were used in PCR with DNA samples from 81-176 (lane 3), 9B6
(lane 4), S3B (lane 5) and JL 141 (lane 6). Lane 1 is standard 1kb ladder
(Promega). (B) Susceptibility of JL 141 and S3B to bile salt using disk diffusion
assay. Wild-type S3B (right) and its putative isogenic cmeB mutant cells were
spread onto MH agar plates. A sterile disk was plated in the center and 10µl of
5% cholic acid was placed on disk. Plates were incubated at 42°C under
microaerophilic conditions for two days.
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(A)

bp

1

2 3 4 5 6 7

10,000
2,000
1,000

23S rDNA
508 bp

500
250

(B)

bp

1

2

3

4

10,000

2,000

cmp
1.3 kb

1,000
500
250

Figure 3. PCR amplification of specific C. jejuni gene fragments for sequence
analysis. A) Amplification of 23S rRNA gene. 23S rRNA gene specific primers
were used in PCR with DNA samples from JL155 (lane 2), JL 156 (lane 3), JL
159 (lane 4), JL 160 (lane 5), JL 187 (lane 6) and JL 188 (lane 7). B)
Amplification of Campylobacter outer membrane protein gene (cmp). cmp
specific primers were used in PCR with DNA samples from inoculated S3B (lane
2), and two isolates from feces (output; lane 3, 4).
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Number of Isolates

16
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6
4
2
0
2

4

8

16

32

64

256 512

Ery MIC Fold Reductions (n-fold)
Figure 4. Effects of MC-207,110 on the susceptibilities of 57 clinical Campylobacter
isolates to erythromycin (Ery).
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Figure 5. Effect of EPI treatment on the colonization of C. jejuni S3B in
chickens. Five-day-old chickens in each group were inoculated with 105 CFU of
C. jejuni S3B via oral gavage. Thirty minutes following C. jejuni inoculation,
MC-207,110 (EPI 1) or MC-04,124 (EPI 2) were orally administered one time at
either high (H) or low (L) dose. The groups were as follows: A) control- no EPI
administered; B) EPI 1 at a high dose of 25 mg/kg; C) EPI 1 at a low dose of 5
mg/kg; D) EPI 2 at a high dose of 150 mg/kg; and E) EPI 2 at a low dose of 30
mg/kg.
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Figure 6. Effect of multiple EPI treatment on the colonization of C. jejuni S3B
in chickens. Five-day-old chickens in each group were inoculated with 105 CFU
of C. jejuni S3B via oral gavage. 30 min., 24 hr. and 48 hr. following C. jejuni
inoculation, MC-207,110 was orally administered at either high (H), medium
(M) or low (L) dose. The groups were as follows: 1) control- no EPI
administered; 2) EPI at a high dose of 75 mg/kg; 3) EPI at a medium dose of 15
mg/kg; 4) EPI at a low dose of 3 mg/kg. A) Percent of chickens colonized with
Campylobacter following treatment. B) Shedding levels of chickens colonized
with Campylobacter following treatment.
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Figure 7. Growth response of C. jejuni 81-176 to CmeC-negative and CmeCpositive serum. The log-phase culture of 81-176 was diluted to approximately
2 x 106 cfu/ml in MH broth containing sublethal concentrations of cholic acid (2
mg/ml). Anti-CmeC and control sera were added to cells with 1:10 dilution and
cells were incubated for 6 hours at 42°C under microaerophilic conditions.
Samples were diluted in MH broth and plated on MH agar plates to determine
bacterial viability. Each bar represents the mean value obtained from triplicate
assays.
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Figure 8. Purification of rabbit IgG by protein G affinity chromatography. (A)
Chromatography of purified rabbit IgG with ImmunoPure (G) IgG Purification
Kit (Pierce). Following collection of unbound protein using 10 ml of binding
buffer (pH 5.0), the bound rabbit IgG was eluted by low pH of elution buffer
(pH 2.8). (B) Analysis of the purification of IgG from rabbit serum by SDSPAGE. Proteins were stained with 0.1% Comassie blue. Lane contents were 1)
molecular mass standard; 2) crude rabbit serum, 1:50 dilution in PBS; 3)
unbound protein which was eluted in the protein G column flowthrough; 4-9)
aliquots from protein G column, corresponding to fraction number 2, 3, 4, 5, 6
and 7, respectively in panel (A).
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